Concepedia

Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany

Anke Stroet, Claudia Hemmelmann, M. Starck, Uwe K. Zettl, Jan Dörr, Friedemann Paul, Peter Flachenecker, Vinzenz Fleischer, Frauke Zipp, Holger Nückel,

Therapeutic Advances in Neurological Disorders · 2012 · 38 citations · 6 references

DOIFull text

Open access

Abstract

Regional differences in reported TRAL incidence may point to confounding cofactors such as administration protocols and cotreatments.

References

6

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

Hans‐Peter Hartung, R Gonsette, Nikolaus König et al. · The Lancet · 2002 · 941 citations

, , +8

Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?

Richard Ellis, M. Boggild · Multiple Sclerosis Journal · 2009 · 89 citations

Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study

Emmanuelle Le Page, Emmanuelle Leray, Gilles Edan · Multiple Sclerosis Journal · 2011 · 84 citations

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis

S. Cotte, Nicolas von Ahsen, Niels Kruse et al. · Brain · 2009 · 74 citations · Full text

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required

Ana María Jiménez Pascual, N. Téllez, Isabel Boscá et al. · Multiple Sclerosis Journal · 2009 · 57 citations

, , +11